Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026
HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
HSR26-237: Meta-Analysis Confirms Venetoclax Plus Decitabine as a Frontline Game-Changer in Elderly AML (Acute Myeloid Leukemia).
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 31, 2026
HSR26-241: Prophylactic G-CSF (Granulocyte Colony-Stimulating Factor) in AML (Acute Myeloid Leukemia) Induction: A Meta-Analysis Dispelling Relapse Concerns and Reinforcing Supportive Benefit.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
HSR26-227: Post-Allogenic Hematopoietic Stem Cell Transplant (Allo-HSCT), Hypomethylating-Agent Maintenance Improves Survival Without Increasing GVHD (Graft Versus Host Disease) in AML/MDS (Acute Myeloid Leukemia/Myelodysplastic Syndrome): Updated Systematic Review and Meta-Analysis.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Showing 1-8 of 8
Last Updated: 09/26/2026